PhI­II fail­ure trig­gers lay­offs, spend­ing cuts and warn­ing of 'dis­so­lu­tion' for sin­gle-mind­ed biotech

When you are stak­ing your whole busi­ness on a make-or-break Phase III tri­al, fail­ure can be dev­as­tat­ing.

Just ask Neu­rana Phar­ma­ceu­ti­cals.

The lit­tle San Diego biotech had en­rolled 1,004 pa­tients who suf­fer from pain due to acute back mus­cle spasms in a Phase III study of its lead drug, tolperisone, as the fi­nal leg of an ef­fort to in­tro­duce to the US a skele­tal mus­cle re­lax­ant that’s been used in Eu­rope since the 1960s.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER